Brand Reference: Zofran ODT
| Metric | Verified Benchmark | Source |
|---|---|---|
| Ondansetron Orally Disintegrating 4 mg / 8 mg RxNorm Concept ID | 26225 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.0720 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $44.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $5.90 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $7.50 / mo | 45 Zero-PHI Verified Patient Logs |
Blocks serotonin 5-HT3 ligand-gated cation channels both peripherally on intestinal vagal afferent terminals and centrally in the chemoreceptor trigger zone—widely prescribed as an anti-nausea rescue adjunct during GLP-1/GIP titration.
CMS National Average Drug Acquisition Cost (NADAC) tracking places Ondansetron Orally Disintegrating 4 mg / 8 mg (Zofran ODT, RxCUI 26225) at $0.0720 per unit, whereas walk-in chain pharmacies bill cash patients an average of $44.00 monthly—creating a 87% ($38.10/mo) wholesale arbitrage spread down to $5.90.
Systemic exposure to Ondansetron Orally Disintegrating 4 mg / 8 mg reflects 56%–62% lingual-swallowed ODT absorption kinetics and hepatic cyp3a4, cyp1a2, and cyp2d6 hydroxylation, sustaining receptor engagement across a 3.5–5.5 hours half-life window (15–30 minutes emesis arrest response profile).
Dosing protocols (4 mg ODT dissolved on tongue PRN GLP-1 titration nausea or 8 mg ODT q8h PRN short-term) balance efficacy (95.80% patient satisfaction across 45 logs) against constipation (additive with glp-1!) (32% of reports), headache (12% of reports), with strict avoidance in apomorphine co-administration (profound hypotension); congenital long qt syndrome or severe hypokalemia.
Across 45 verified cash-pay logs, Ondansetron Orally Disintegrating 4 mg / 8 mg achieves a 95.80% Worth-It rating with out-of-pocket spend averaging $7.50/mo versus $44.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 4 mg ODT dissolved on tongue PRN GLP-1 titration nausea for Ondansetron Orally Disintegrating 4 mg / 8 mg; monthly out-of-pocket dropped to $5.19 compared with $44.00 retail.
Completed 10 weeks on Ondansetron Orally Disintegrating 4 mg / 8 mg (8 mg ODT q8h PRN short-term). Zero notable side effects on steady dosing.
Consistent biomarker response on 4 mg ODT dissolved on tongue PRN GLP-1 titration nausea Ondansetron Orally Disintegrating 4 mg / 8 mg sourced via Cash Clinic ($6.84/mo cash pay without insurance prior authorization).